Neoadjuvant Nivolumab in Glioblastoma
Neoadjuvant nivolumab will be administered to patients with primary and recurrent glioblastoma multiforme that require surgery. Nivolumab will be continued following surgery.
Glioblastoma Multiforme
DRUG: Nivolumab
Changes in percentage and level of expression of Programmed Death-Ligand 1 (PD-L1) by tumor cells and lymphocytes, assessed at baseline and following neoadjuvant nivolumab in Glioblastoma multiforme (GBM)., We will assess levels of expression of Programmed Death-Ligand 1 (PD-L1) by tumor cells and lymphocytes at baseline and following neoadjuvant nivolumab in Glioblastoma multiforme (GBM). The specific outcome will be the changes in these levels., 1 neoadjuvant cycle followed by surgery (4 weeks). Evaluation will be performed at baseline and after the neoadjuvant cycle
Efficacy: response rate assessed by Response Assessment in Neuro-Oncology (RANO) criteria, 1 neoadjuvant cycle followed by surgery (4 weeks)|Safety: toxicity assessed by Common Toxicity Criteria (CTC) version 4, 1 neoadjuvant cycle followed by surgery (4 weeks)
Neoadjuvant nivolumab will be administered to patients with primary and recurrent glioblastoma multiforme that require surgery. Nivolumab will be continued following surgery until toxicity or progression.